362 studies found for:    "hemophilia"
Show Display Options
Rank Status Study
21 Completed The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs
Conditions: Hemophilia A;   Hemophilia B
Interventions: Behavioral: Counseling;   Behavioral: Control
22 Recruiting A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care
Conditions: Haemophilia A;   Haemophilia B
Intervention:
23 Completed Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
24 Recruiting Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS
Conditions: Hemophilia A;   Hemophilia B
Interventions: Biological: ADVATE (Antihemophilic Factor [Recombinant]);   Biological: RIXUBIS (Coagulation Factor IX [Recombinant])
25 Completed Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
26 Recruiting A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
Conditions: Hemophilia A;   Hemophilia B
Interventions: Drug: ALN-AT3SC;   Drug: Sterile Normal Saline (0.9% NaCl)
27 Completed Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: NNC 0128-0000-2011
28 Completed Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors
Conditions: Hemophilia A;   Hemophilia B
Interventions: Drug: BAY Factor VII (BAY86-6150);   Drug: Placebo
29 Completed Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B;   Healthy
Interventions: Drug: NNC 0172-0000-2021;   Drug: placebo
30 Recruiting An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Conditions: Hemophilia A;   Severe Hemophilia A
Intervention: Biological: rVIII‑SingleChain
31 Completed Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
32 Completed Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII, long acting
33 Completed Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
34 Completed Trial of NovoSeven® in Haemophilia - Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: activated recombinant human factor VII;   Drug: Feiba VH
35 Completed Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Condition: Hemophilia A
Intervention: Biological: OBI-1
36 Terminated
Has Results
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A
Condition: Hemophilia A
Intervention: Biological: OBI-1
37 Completed
Has Results
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: vatreptacog alfa (activated);   Drug: eptacog alfa (activated)
38 Completed Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Intervention: Drug: activated recombinant human factor VII
39 Completed Hemophilia Inhibitor Genetics Study (HIGS)
Condition: Hemophilia A With Inhibitor
Intervention: Procedure: Blood draw
40 Completed Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Intervention: Drug: eptacog alfa (activated)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years